This PD-1 target evaluation report is generated based on structured data from PatSnap Target & Disease MCP and PatSnap Clinical Trials MCP.
Executive Summary — Target Thesis
Approved Drugs
23
Global, as of mid-2026
Registered Trials
9,166
NCT-registered globally
Bispecifics in Pipeline
143
3 approved; dominant trend
✓
Key Strengths
- Fully validated target. Most heavily validated IO target in pharmaceutical history — genetic, mechanistic, and disease-causality evidence all established.
- Bispecific superiority proven. HARMONi-6: ivonescimab OS HR=0.66 vs PD-1+chemo (mOS 27.9 vs 23.7 mo) — first bispecific to beat PD-1+chemo head-to-head.
- Capital confirming next-gen thesis. AbbVie/RemeGen $650M upfront / $5.6B total for PD-1×VEGF bispecific (Jan 2026).
- Expanding into new settings. GBM positive signal (pembrolizumab+TTFields+TMZ, Phase 3, n=741); cold tumors (INCA-33890 mCRC MSS).
- White-space indications. PD-1×angiogenesis beyond NSCLC, PD-1×IL-2 cytokine fusion, neoadjuvant resectable settings.
!
Key Risks
- mAb commoditization accelerating. Pembrolizumab US patent ~2028; biosimilar NDA/BLA filings already active (FYB206, BAT3306).
- Primary resistance ~60–70%. Single-agent mAb insufficient in most NSCLC patients; redundant co-inhibitory pathways (TIM-3, TIGIT, LAG-3, VISTA) drive escape.
- irAE burden. Grade 3+ irAEs require systematic DSMB tracking; bispecific/combination formats carry stricter criteria than monotherapy.
- Bispecific competition intensifying. AbbVie/RemeGen RC-148 directly challenging ivonescimab; PD-1×TIM-3 and PD-1×TIGIT in Phase 3.
- Intratumoral Treg signal. PD-1 on Tregs provides stabilization/proliferative signals — systemic blockade has dual effects complicating dose/combination design.
Target Benchmark Snapshot
| Dimension | Current Evidence | Benchmark | Strategic Meaning |
|---|---|---|---|
| Biological validation | Genetic (SLEB2 locus, GWAS), mechanistic (SHP-2 pathway, T-cell exhaustion), disease-causality | Among most validated oncology targets | Highest confidence; no biology de-risking needed |
| Approved assets | 23 approved drugs (global); mono-mAbs, bispecifics, CAR-T, subQ formulations | PD-L1: ~8 approvals; CTLA-4: 2 | Most crowded approved class in oncology IO |
| Late-stage pipeline | 29 drugs in Phase 3 (including 7+ bispecifics); 426 active/recruiting Phase 3 trials | VEGFR2 combos, TIM-3 bispecifics | Near-term additions primarily bispecific or combo |
| Modality spread | mAbs (184), Bispecifics (143), Small molecules (78), Biologic fusions, CAR-T | LAG-3: mono-mAb only | Bispecific surge is dominant trend; small molecules niche |
| Clinical benchmark | Ivonescimab HARMONi-6 OS HR=0.66 vs PD-1+chemo; nivo+ipi CM-9DW 21% CR in HCC | Pembrolizumab KEYNOTE-024 PFS HR=0.50 in NSCLC (PD-L1≥50%) | Best-in-class bar rising; mAb monotherapy insufficient for most |
| Deal activity | 278 total deals; top: AbbVie/RemeGen PD-1×VEGF bispecific $650M upfront / $5.6B total (Jan 2026) | PD-L1 deals: smaller; LAG-3: sparse | Capital flowing to bispecifics; biosimilar deals dominant for Asia |
Section I · Target Biology and Druggability
- Protein Class
- Type I transmembrane glycoprotein
- IgV extracellular domain
- Localization
- Inhibitory receptor on activated T-cells
- Immunological synapse
- Associated Diseases
- 952
- Oncology dominant
- Druggability
- High confidence
- mAbs, bispecifics, sm, fusions
Signaling Cascade — PD-1 Inhibitory Mechanism
Multi-layer Mechanism of Action — PD-1 Blockade
1
2
3
4
Section II · Pipeline and Modality Landscape
Pipeline by Modality (769 Total Assets)
mAbs
184
Bispecifics
143
Small mol.
78
Phase 3
29
Approved
23
Bispecific Co-target Landscape (143 assets)
Ivonescimab class · Anti-angiogenic synergy
Cadonilimab approved; dual checkpoint
Rilvegostomig (AZ/Merck) · Phase 3
Volrustomig (AZ) · NSCLC + GI · Phase 3
Approved Assets (23 Total · Selection)
| Asset | Company | Modality | First Approval | Key Indication | Geography |
|---|---|---|---|---|---|
| Nivolumab | BMS / Ono | mAb | Jul 2014 | Melanoma → 462 diseases | Global |
| Pembrolizumab ★ | Merck | mAb | Sep 2014 | Melanoma → 328 diseases | Global |
| Cemiplimab | Sanofi/Regeneron | mAb | Sep 2018 | Cutaneous SCC, NSCLC, BCC | US/EU |
| Toripalimab | Junshi/Coherus | mAb | Dec 2018 | NPC → US approved 2023 | Global |
| Sintilimab | Innovent | mAb | Dec 2018 | HL, NSCLC, GC, HCC | Multiple |
| Tislelizumab | BeiGene | mAb | Dec 2019 | NSCLC, ESCC, HCC | Global (incl. EU/US) |
| Dostarlimab | GSK/Tesaro | mAb | Apr 2021 | Endometrial, dMMR solid tumors | US/EU |
| Nivolumab/Relatlimab | BMS | Combo mAb | Mar 2022 | Melanoma | US/EU |
| Cadonilimab ★ | Akeso | Bispecific | Jun 2022 | Cervical cancer, GC/GEJ | Multiple |
| Ivonescimab ★ | Akeso/Summit | Bispecific | May 2024 | NSCLC | Multiple |
| Nivolumab/Hyaluronidase | BMS | mAb (subQ) | Dec 2024 | NSCLC, RCC, melanoma | US |
| Pembrolizumab/Hyaluronidase | Merck | mAb (subQ) | Sep 2025 | Multiple | US |
★ = competitive leaders; full 23-drug list includes additional assets not shown
Phase 3 Pipeline — 29 Assets (Selection)
| Asset | Company | Modality | Target Pair | Lead Indication | Differentiation |
|---|---|---|---|---|---|
| Ivonescimab | Akeso/Summit | Bispecific | PD-1×VEGF-A | NSCLC (global expansion) | OS benefit vs. PD-1+chemo proven (HARMONi-6) |
| Volrustomig | AstraZeneca | Bispecific | PD-1×TIGIT | NSCLC, GI | Dual checkpoint co-inhibition |
| Rilvegostomig | AZ/Merck | Bispecific | PD-1×TIM-3 | Multiple solid tumors | TIM-3 addresses T-cell exhaustion |
| IBI-363 | Innovent | Fusion/Bsp | PD-1×IL-2 | Solid tumors | IL-2 cytokine armoring — immune boosting |
| INCA-33890 | Incyte | Bispecific | PD-1×novel | mCRC (MSS) | Addresses immunologically cold tumors |
| RC-148 | RemeGen | Bispecific | PD-1×novel | sqNSCLC | Head-to-head vs. tislelizumab |
| Sasanlimab | Pfizer | mAb | PD-1 | Bladder, lung | Combination-focused |
| Fianlimab+Cemiplimab | Regeneron | Dual mAb combo | PD-1+LAG-3 | Melanoma, NSCLC | LAG-3 co-inhibition |
Section III · Clinical Evidence Benchmark
HARMONi-6 · Ivonescimab
HR=0.66
OS vs Tislelizumab+Chemo
sq-NSCLC 1L · n=532 · mOS 27.9 vs 23.7 mo
★ ASCO 2026 Plenary · First bispecific to beat PD-1+chemo
CheckMate-9DW · Nivo+Ipi
21% CR
OS/CR vs Lenvatinib/Sorafenib
Unresectable HCC 1L · 4-yr follow-up · 1–6% CR in comparator
Full Evidence Benchmark Summary
| Asset / Regimen | Trial | Population | Endpoint | Result | Evidence Type |
|---|---|---|---|---|---|
| Ivonescimab+Chemo | HARMONi-6 | sq-NSCLC 1L (n=532) | OS | mOS 27.9 vs 23.7 mo; HR=0.66 | Phase 3 RCT head-to-head, positive |
| Pembrolizumab | KEYNOTE-024 | NSCLC PD-L1≥50% 1L | PFS | HR≈0.50 | Prospective RCT |
| Nivolumab+Ipilimumab | CheckMate-9DW (4-yr FU) | Unresectable HCC 1L | OS/CR | 21% CR vs 1–6% | Phase 3, positive |
| Cadonilimab+Chemo | CONQUEST | IT-refractory NPC R/M | PFS/OS | Positive | Prospective RCT |
| Pembrolizumab+TTFields+TMZ | EF-41/KEYNOTE-D58 (n=741) | Newly diagnosed GBM | OS | Positive vs TTFields+TMZ+placebo | Phase 3 RCT (novel indication) |
| Tislelizumab (periop) | RATIONALE-315 | Resectable GEJ/gastric | EFS by surgical subgroups | Positive subgroup | Phase 3 post-hoc |
Section IV · Competitive Ranking
PD-1 Competitive Leaderboard — Top 5 Assets
Ranked by commercial + clinical footprint
| Rank | Asset / Company | Modality | Indications | Trials | Key Strength | Key Risk | Next Catalyst |
|---|---|---|---|---|---|---|---|
| 1 | Pembrolizumab Merck |
mAb + subQ | 328 | 2,635 | Deepest portfolio; most TM records (2,343); subQ approved | US patent ~2028; biosimilar NDA/BLA active | Biosimilar launch timeline; MK-3475A combos |
| 2 | Ivonescimab Akeso+Summit |
Bispecific (PD-1×VEGF) | Approved 2024 | Expanding | First bispecific to demonstrate OS superiority vs PD-1+chemo (HARMONi-6) | Data still maturing globally; AbbVie/RemeGen competing | HARMONi-A global OS readout; US NDA/BLA |
| 3 | Nivolumab BMS / Ono |
mAb + subQ | 462 | Strong | 462 diseases; strong combo platform (ipi+nivo, nivo+rela, subQ); 4-yr HCC 21% CR | Losing NSCLC market share to pembrolizumab; patent risk | Nivo/rela expansion; HCC long-term OS; subQ penetration |
| 4 | Tislelizumab BeiGene |
mAb | EU/US approved | 14 deals | Most active deal asset; Eisai Japan deal ($388M); global expansion | Mid-tier vs pemb/nivo; RC-148 Ph3 head-to-head | RC-148 Ph3 readout; additional indications |
| 5 | Cadonilimab Akeso |
Bispecific (PD-1×CTLA-4) | Cervical + GC/GEJ | CONQUEST positive | First approved PD-1×CTLA-4 bispecific; CONQUEST positive in NPC | Asia approvals only; CTLA-4 toxicity concern | Global registrational filings; combination data |
Section V · IP Landscape and Strategy
Patent Lifecycle — Key Events
-
Core composition patent — expired or expiring; door open for biosimilar/biobetter
-
Pembrolizumab US composition patent expiry (Merck)
-
Earliest priority expired; use patents extend to ~2030; biosimilar wave imminent
-
WO-series active/pending · 10–15 year exclusivity window · AbbVie $5.6B deal validates IP value
-
e.g. US20210148920A1 — LAT1 biomarker for PD-1 response; CDx IP forms defensive moat
-
US approved 2024–2025; defensible reformulation moat extending beyond IV patent expiry
-
irAE reversal agents — WO2025107419A1
Active/pending mAb families (Synapse DB)
Section VI · Deal Intelligence
Jan 2026 · Exclusive License
$5.6B
$650M upfront + $4.95B milestones
Signal: Bispecific IP validated at $5B+ valuation
Feb 2026 · License
Serplulimab (HLX-10) Japan rights
$388M
$75M upfront + $313M milestones
Signal: Approved mAb still valuable under JP IP regime
May 2026 · Royalty Purchase
$80M
$60M upfront + $20M milestones
Signal: Niche mAb monetized via royalty finance
Recent Deal Intelligence — Full Log
| Date | Parties | Asset | Type | Value | Signal |
|---|---|---|---|---|---|
| Jan 2026 | RemeGen → AbbVie | PD-1×VEGF bispecific (RC-148) | Exclusive license | $650M up + $4.95B milestones | AbbVie entering next-gen IO; confirms PD-1 bispecifics >$5B value |
| Feb 2026 | Henlius → Eisai | Serplulimab Japan rights | License | $75M up + $313M milestones | Approved mAb valuable in Japan under different IP regime |
| Feb 2026 | Formycon → Lotus Pharmaceutical | FYB206 (pembro biosimilar) Asia-Pacific | Distribution | Undisclosed | Biosimilar commercialization accelerating in Asia-Pacific |
| Jan 2026 | BostonGene → Ottimo Pharma | PD-1/VEGFR2 combo IO therapy | AI collaboration | Undisclosed | AI-driven optimization of PD-1 combo entering development |
| May 2026 | MacroGenics → Sagard Healthcare | ZYNYZ® (retifanlimab) royalty | Royalty purchase | $60M up + $20M milestones | Approved niche mAb monetized via royalty finance |
| Apr 2026 | BeOne ← Huahui Health | Pre-clinical PD-1 related (global rights) | License (global) | $20M up + $1.97B milestones | BeOne consolidating global rights to early-stage PD-1 assets |
Section VII · White Space and Risks
▲ Bull Case — Opportunities
- 2026 HARMONi-A global OS readout. Ivonescimab global trial — confirmation would accelerate bispecific displacement of mAb monotherapy.
- 2026 GBM IO breakthrough. Pembrolizumab+TTFields+TMZ positive Phase 3 (EF-41/KEYNOTE-D58, n=741) opens neuro-oncology IO strategy.
- 2026 Cold tumor first signal. INCA-33890 positive Phase 3 in FOLFOX+bev combination for mCRC (MSS) — opens new indication class for PD-1 combos.
- 2027 PD-1×IL-2 (IBI-363) Phase 3 data. Cytokine armoring could be best-in-class for tumors with exhausted-enriched microenvironment.
▼ Bear Case — Risks
- 2028 Pembrolizumab US patent expiry + biosimilar entry. FYB206, BAT3306 and others accelerating — revenue erosion for innovator mAbs; pricing pressure in Asia 3–5 years ahead.
- NOW Primary resistance ~60–70% NSCLC. Single-agent mAb insufficient — combination partners required. Biomarker-defined selection (TMB, MSI, inflamed phenotype) critical.
- NOW irAE Grade 3+ burden. Bispecific/combination formats carry stricter DSMB criteria; irAE management protocols are essential given growing post-market safety data.
- 2026–27 HARMONi-A replication failure risk. If global trial fails to confirm HARMONi-6 OS HR=0.66, bispecific superiority thesis requires revision.
Risk Heatmap — Severity × Probability
LOW
MEDIUM
HIGH
HIGH
R3
R1
MED
R2
R4
LOW
← Probability →
Clinical/IP
Commercial
R1
Primary/Acquired Resistance (~60–70% NSCLC)
Co-inhibitory pathway redundancy (TIM-3, TIGIT, LAG-3, VISTA) drives primary and acquired resistance; single-agent mAb insufficient for most patients.
Mitigation: Mechanistic combination strategies; bispecifics targeting two pathways simultaneously; biomarker-stratified enrollment.
R2
Biosimilar Commoditization of Core mAb Market
Multiple pembrolizumab/nivolumab biosimilar partnerships active (FYB206, BAT3306); revenue erosion for innovator mAbs; pricing pressure in Asia 3–5 years ahead of US.
Mitigation: Innovator subQ reformulations and next-gen bispecific combos; premium market defense in US/EU.
R3
irAE Management Burden
Grade 3+ irAE incidence must be systematically tracked; bispecific/combination formats carry stricter DSMB criteria than historic monotherapy trials.
Mitigation: irAE reversal agents in development (WO2025107419A1); standardized DSMB protocols for bispecific programs.
Section VIII · R&D Strategy Implications by Audience
BD Decision-Makers
✗
Avoid: Pure anti-PD-1 mAb licensing unless extraordinary niche (novel indication with breakthrough designation potential, or low-cost biosimilar in emerging markets).
✓
●
R&D Decision-Makers
✓
Invest in: Next-gen bispecific formats with mechanistically synergistic co-targets; neoadjuvant combinations in resectable settings (EFS/pCR endpoints); biomarker-stratified populations.
✓
De-risk by: Cross-referencing against the 29-drug Phase 3 pipeline; confirm target indication is not crowded with multiple Phase 3 competitors; identify 2–3 indications where clinical bar is unestablished.
●
Critical choice: Co-formulated bispecific (ivonescimab model) vs. sequential combination dosing — PK/PD arguments favor co-formulated for receptor occupancy and half-life optimization.
R&D Execution Teams
◆
◆
Trial design: If testing a bispecific, include a PD-1 monotherapy control arm; cross-trial comparisons are no longer acceptable as primary evidence given volume of head-to-head data available.
!
Safety monitoring: irAE Grade 3+ must be systematically tracked; DSMB criteria for bispecific/combination formats are stricter than historic monotherapy trials.
Bottom Line
PD-1 is the most clinically and commercially validated oncology target ever developed — with 23 approved drugs, 9,166 clinical trials, and 278+ active deals. The target is entering a structural transition: the first generation (pure anti-PD-1 mAbs by Merck/BMS) is moving toward commoditization and biosimilar entry, while the second generation (PD-1-based bispecifics and subQ reformulations) is now clinically proving superiority over the first. The HARMONi-6 readout (ivonescimab OS HR=0.66 vs. PD-1+chemo, ASCO 2026 Plenary) is the defining evidence of this transition. Capital allocation is following the biology: the $5.6B AbbVie/RemeGen bispecific deal (January 2026) signals where premium value will reside. For R&D and BD teams, the actionable thesis is simple: PD-1 biology remains validated and commercially compelling, but competitive differentiation now requires a bispecific or mechanistically novel combination architecture — a solo anti-PD-1 mAb program without unique biology cannot win in the current landscape.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers